Gene Expression Analysis Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 8.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Gene Expression Analysis Market Analysis
The Gene Expression Analysis Market is projected to register a CAGR of 8.9% during the forecast period.
The COVID-19 pandemic is expected to have a positive effect on the gene expression analysis market. The development of therapeutic and preventive strategies requires an accurate understanding of the role that genomes play in the SARS-CoV-2 infection process and progression of COVID-19. The vast field of genomics is well equipped with the technologies needed to help in facing this challenge. A rise in the analysis of gene expression profiles of SARS-CoV-2 receptors for in silico drug discovery for COVID-19 is a high-impact rendering driver for the segment. For instance, according to an article published in the Antibiotics journal, in March 2022, titled " The Impact of Multiplex PCR in Diagnosing and Managing Bacterial Infections in COVID-19 Patients Self-Medicated with Antibiotics', multiplex polymerase chain reaction (PCR), a powerful and efficient tool, is used to diagnose SARS-CoV-2 infections and that has applications for bacterial identification, as well as determining bacterial resistance to antibiotics. Additionally, a study published in the Frontiers in Genetics publications in May 2022 stated that in COVID-19 patients, the gene profiling and analysis of certain common differentially expressed genes (co-DEGs) could be used for the diagnosis and management of the thrombosis and anticoagulant therapy in the COVID-19 patients. The gene expression analysis of the co-DEGs, along with their biological potential functions, protein-protein interactions, functional enrichment analysis, and study of their molecular mechanisms. Thus, the COVID-19 pandemic is leading to an increased demand for gene expression analysis for detecting coronavirus infection among the population.
Certain factors that are propelling the market growth are increasing government funding regarding genomics, rising technological advancements, and growing adoption of personalized medicine.
Gene expression has emerged as one of the key technologies and is widely used at various stages of the drug development process, such as drug discovery and development procedures, clinical diagnostics, biotechnology, microbiology, and others. The limitations in using existing technologies for disease detection and developing precision medicines have increased the demand for newer technologies which is expected to increase the demand for gene expression analysis, hence propelling the market growth. For instance, the use of microarrays during drug development is constrained by hybridization-based detection and the usage of predesigned oligonucleotide probes. However, the development of Cap Analysis of Gene Expression (CAGE), which enables thorough mapping of the promoters and initiation sites of human transcription, has assisted in overcoming the issue. The method also enables cellular mRNA measurement.
Additionally, with the rise in genetic disorders and increased public awareness of personalized medicine, the need for personalized medicine is expected to develop rapidly over the forecast period. Additionally, the increasing focus of companies in adopting various business strategies such as partnerships, collaborations, and financing to develop precision therapies is promoting the use of personalized medicines among the public and is expected to drive the market. For instance, in May 2022, Illumina entered into a long-term strategic collaboration with Janssen Biotech to accelerate the development of precision medicines. Under this collaboration, the company utilizes Illumina's portfolio of resources, including AI-based genome interpretation tools, whole-genome sequencing, and multi-omic analysis services, for co-developing CDx programs on TruSight Oncology Comprehensive assay, a single test that assesses multiple tumor genes and biomarkers in a patient's cancer.
Furthermore, developing technologically advanced solutions and increasing company activities for developing genomic solutions for various diseases are anticipated to boost market growth over the forecast period. For instance, in July 2022, Epic Bio was launched by the CRISPR Pioneer and received funding of USD 55 million. Epic Bio has developed advanced gene expression systems known as the GEMS (Gene Expression Modulation System) platform, which offers precise modification of gene expression. GEMs consist of the largest library of known novel modulators along with computational genomics capabilities and advanced functions, which are used in the designing of guide RNAs for target genes. Also, in November 2021, Emmes, a Clinical Research Organization (CRO), partnered with MedGenome to accelerate breakthrough treatments powered by human genomics for rare disease patients. This partnership helps in bringing more innovative treatments to patients who are suffering from rare diseases.
However, factors such as lack of skilled labor and the high cost of instruments are likely to restrain the market growth over the forecast period.
Gene Expression Analysis Market Trends
This section covers the major market trends shaping the Gene Expression Analysis Market according to our research experts:
Next Generation Sequencing (NGS) Segment Expects to Register a High CAGR in the Forecast Period
Next-Generation Sequencing (NGS) is a technology that is used to determine the sequence of DNA or RNA to study the genetic variations associated with the disease. It is also called as massively-parallel sequencing as it enables the sequencing to determine the sequencing of millions of DNA at a particular time.
The next-generation sequencing is expected to witness significant growth over the forecast period owing to the factors such as an upsurge in the use of NGS technology in clinical diagnosis, speed, cost, and accuracy of the sequencing method. In addition, the advantage over NGS, which provides precision results from the low sample input, over Sanger's sequencing method is also driving the market growth.
The increasing use of next-generation sequencing technology in various applications such as biomarker discovery, oncology studies, and personalized medicine is the key factor driving the market growth. For instance, the fast emergence of next-generation sequencing technology has revolutionized the field of genomics and medical diagnosis and has changed the traditional model of a gene-by-gene approach to syndrome-based panel sequencing, diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS), precision model. According to the Centers for Disease Control, 2021, it is projected that more than 60 million people will have their genomes sequenced by 2025 worldwide as countries have taken the initiative to sequence large populations. Additionally, Cell-free plasma next-generation sequencing (cfNGS) is used to detect the infection caused by viral, bacterial, and fungal agents by detecting pathogen DNA in the blood. Furthermore, the Cell-free plasma next-generation sequencing has been used in adults with sepsis, oncology patients, and healthy children with community-acquired pneumonia. Thus, the increasing use of next-generation sequencing technology in various diseases is expected to increase segment growth over the forecast period.
Furthermore, numerous initiatives undertaken by universities, academic and research institutions, and research establishments for utilizing next-generation sequencing technology in identifying the root cause of diseases are likely to propel the segment growth. For instance, in December 2021, Roche launched the AVENIO Edge System to advance next-generation sequencing (NGS) technologies. Similarly, in January 2021, Cerba Research launched two COVID-19 exploratory tools, PCR-based and Next-Generation Sequencing-based, to enhance research for vaccine development against infectious diseases, including COVID-19. The whole-genome sequencing of respiratory viruses and SARS-CoV-2 was greatly simplified using the next-generation sequencing-based test. Such developments are a major boost to clinical studies and organizations progressing with next-generation sequencing as their basis of innovation.
Thus, increasing use of next-generation sequencing technology and rising initiatives by companies, universities, and research institutes for utilizing next-generation sequencing in developing effective treatments and therapies for diseases are expected to boost segment growth over the forecast period.
North America Dominates the Market and Expects to do Same in the Forecast Period
North America dominates the global gene expression analysis market and is expected to maintain its dominance over the forecast period. This growth can be attributed to rising investment and increasing research and development activities toward the development of gene therapy, especially in the United States. In addition, factors such as the increasing focus on gene expression studies, government initiatives, and the availability of funding for next-generation sequencing (NGS) research are driving the growth of the gene expression analysis market in North America.
The rising funding by research institutes, companies, and universities for next-generation sequencing is also contributing to the growth of the market in the region. For instance, in August 2022, the Department of Health and Human Services announced funding of funding opportunity announcement (FOA) for innovative research and study of structural birth defects with the use of human translational/clinical approaches (genomics, metabolomics, proteomics, etc.) and animal models. Some of the research areas covered in the FOA included the identification of the associated modifier genes which impacts the variability and susceptibility of the structural birth defects gene expression and the study of the altered gene expression and epigenetic factors (effectors of structural birth defect) and imprinting.
Moreover, the increasing company focus on research and development activities for developing gene therapy products, as well as methods that involve gene expression analysis and the rising adoption of various business strategies such as product launches, partnerships, collaborations, and acquisitions, are also contributing to the growth of the market. For instance, in May 2022, Bio-Rad Laboratories, Inc. launched its new CFX Duet Real-Time PCR System, which offers singleplex and duplex quantitative PCR (qPCR) assays. The system would enable multiple gene expression analyses and precise quantification analysis of up to two targets in genotyping without using dye. Also, in December 2021, Microbix Biosystems launched single-unit swab-formatted control to their range of Quality Assessment Products ('QAPsTM'), which simultaneously supports PCR tests for SARS-CoV-2 ('COVID'), Influenza A ('Flu A'), Influenza B ('Flu B'), and Respiratory Syncytial Virus ('RSV'), four of the most frequent causes of viral infectious respiratory infection worldwide. Such initiatives are anticipated to increase the demand for gene expression analysis, thereby contributing to market growth. Similarly, in November 2021, Regeneron Pharmaceuticals expanded the research term of its strategic partnership with Decibel Therapeutics, to discover and develop gene therapies for hearing loss.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period in the region.
Gene Expression Analysis Industry Overview
The market studied is moderately consolidated, owing to the presence of many small and large market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some market players are QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Illumina, Inc., Novogene Corporation, PerkinElmer Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, Promega Corporation, and Luminex Corporation. Regional and service portfolio expansions and mergers and acquisitions are key strategic undertakings adopted by these players.
Gene Expression Analysis Market Leaders
-
Quest Diagnostics Incorporated
-
Illumina, Inc.
-
PerkinElmer Inc.
-
Agilent Technologies
-
Promega Corporation
*Disclaimer: Major Players sorted in no particular order
Gene Expression Analysis Market News
- January 2023: QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, launched its QIAGEN CLC Genomics Workbench Premium, which removes the data-analysis bottleneck of next-generation sequencing. The bottleneck of the NGS data analysis is offered by adding high analysis speed to the analysis and interpretation of the whole exome sequencing (WES), whole genome sequencing (WGS), and large panel sequencing data.
- October 2022: Kite, a Gilead Company, signed an exclusive worldwide license agreement with Refuge Biotechnologies, Inc. Under the agreement, Refuge's proprietary gene expression platform would be utilized for the development of blood cancer therapy. The Refuge's proprietary gene expression platform consists of an expression modulation strategy that represses or activates the target genes' transcription, which has been found helpful in CAR T (chimeric antigen receptor T)-cell therapy.
- March 2022: The University of Mississippi Medical Center set up clinical next-generation sequencing (NGS) machine, a first-in-the-state resource. It allows physicians to assess the DNA sample from cancer patients faster and more cost-efficient.
Gene Expression Analysis Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rapid Technological Advancement
4.2.2 Increased Government Funding towards Genomics
4.2.3 Growing Adoption of Personalized Medicine
4.3 Market Restraints
4.3.1 Lack of Skilled Labor
4.3.2 High Cost of the Instruments
4.4 Porter Five Forces
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Technology
5.1.1 Polymerase Chain Reaction (PCR)
5.1.2 Next Generation Sequencing (NGS)
5.1.3 Microarrays
5.1.4 Others
5.2 By Product Type
5.2.1 Instruments
5.2.2 Reagents and Consumables
5.2.3 Services
5.3 By End-user
5.3.1 Drug Discovery & Development
5.3.2 Diagnostic Laboratories
5.3.3 Academic Research Centers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 QIAGEN
6.1.2 Quest Diagnostics Incorporated
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Illumina, Inc.
6.1.5 Novogene Corporation
6.1.6 PerkinElmer Inc.
6.1.7 Bio-Rad Laboratories
6.1.8 Thermo Fisher Scientific, Inc.
6.1.9 Agilent Technologies
6.1.10 Promega Corporation
6.1.11 Luminex Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Gene Expression Analysis Industry Segmentation
As per the scope of this report, gene expression makes an analysis of the study of the activity or occurrence of the making of a gene product from its coding gene. This process is considered a delicate indicator of biological activity in which a change in the gene expression pattern leads to a change in the biological process. The gene expression analysis typically involves the isolation or capture of transcribed RNA within a sample, followed by amplification and subsequent detection and quantitation. The Gene Expression Analysis Market is segmented by Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Microarrays, and Others), Product (Instruments, Reagents and Consumables, and Services), End-user (Drug Discovery, Diagnostic Laboratories, and Academic Research Centers), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Technology | |
| Polymerase Chain Reaction (PCR) | |
| Next Generation Sequencing (NGS) | |
| Microarrays | |
| Others |
| By Product Type | |
| Instruments | |
| Reagents and Consumables | |
| Services |
| By End-user | |
| Drug Discovery & Development | |
| Diagnostic Laboratories | |
| Academic Research Centers |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Gene Expression Analysis Market Research FAQs
What is the current Global Gene Expression Analysis Market size?
The Global Gene Expression Analysis Market is projected to register a CAGR of 8.90% during the forecast period (2024-2029)
Who are the key players in Global Gene Expression Analysis Market?
Quest Diagnostics Incorporated, Illumina, Inc., PerkinElmer Inc., Agilent Technologies and Promega Corporation are the major companies operating in the Global Gene Expression Analysis Market.
Which is the fastest growing region in Global Gene Expression Analysis Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Gene Expression Analysis Market?
In 2024, the North America accounts for the largest market share in Global Gene Expression Analysis Market.
What years does this Global Gene Expression Analysis Market cover?
The report covers the Global Gene Expression Analysis Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Gene Expression Analysis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Gene Expression Analysis Industry Report
Statistics for the 2024 Global Gene Expression Analysis market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Global Gene Expression Analysis analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Global Gene Expression Analysis Report Snapshots
